This compound has attracted interest in laboratory studies related to cellular metabolism, biochemistry, and molecular research, and is applied solely in non-clinical research contexts
That triggered pushback from wellness entrepreneurs, compounding pharmacies and their allies in Washington
BPC-157 TB-500 10mg Peptide Premium Research Blend (Wolverine Stack) The BPC-157 TB-500 10mg peptide blend from Astra Labs is a premium lyophilised research compound combining two of the most extensively discussed peptides in research literature
The Journal of Clinical Endocrinology and Metabolism
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday